NDA 018680 · Coopersurgical
Paragard T 380a
Copper · Intrauterine · Copper-containing Intrauterine Device
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1984
Nov 15, 1984
Approved uses
6
Original approval plus efficacy supplements
Registered trials
158
26 Phase 3, 16 recruiting
FAERS reports
43,152
19,749 serious, 60 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 19, 2026.
Paragard is indicated for prevention of pregnancy in females of reproductive potential for up to 10 years. Paragard is a copper-containing intrauterine system (IUS) indicated for prevention of pregnancy in females of reproductive potential for up to 10 years. ( 1 )
Mechanism: Copper continuously released into the uterine cavity contributes to the contraceptive effectiveness of Paragard. Mechanism(s) by which copper enhances contraceptive efficacy include interference with sperm transport and fertilization of an egg, and possibly prevention of implantation.
Therapeutic areas: Endocrinology and women's health
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 28, 2024 Supplement 74 · Efficacy LabelLetterReview
- Sep 1, 2005 Supplement 60 · Efficacy LabelLetter
- May 19, 1994 Supplement 26 · Efficacy
- Aug 13, 1991 Supplement 16 · Efficacy
- Jul 17, 1989 Supplement 8 · Efficacy
- Nov 15, 1984 Original approval · Type 3 - New Dosage Form Review
1 products under this application
- PARAGARD T 380A · COPPER 309MG/COPPER · SYSTEM, INTRAUTERINE · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Copper" as an intervention, any sponsor and status, largest first.
- The Evidence for Contraceptive Options and HIV Outcomes TrialPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT02550067 · 7,830 participants · Start Dec 14, 2015 · Primary completion Oct 31, 2018
Drug: DMPA; LNG and 1 more · For: HIV; Contraception
Sites: Manzini, Eswatini; Kisumu, Kenya; Brits, South Africa · 12 sites in all
- Evaluation of Efficacy, Safety and Tolerability of VeraCept IUSPivotal-lookingActive, not recruiting
Sebela Women's Health Inc.Industry
NCT03633799 · 1,620 participants · Start Aug 22, 2018 · Primary completion Sep 22, 2022
Drug: VeraCept · For: Women at Risk for Pregnancy
Sites: Scottsdale, Arizona; Tucson, Arizona; Berkeley, California · 41 sites in all
- LF111 or Drospirenone Chew vs Non-hormonal Contraceptive Methods on Bone Mineral Density in Adolescent and Adult WomenActive, not recruiting
Insud PharmaIndustry
NCT05303636 · 1,536 participants · Start Mar 28, 2022 · Primary completion Dec 2027
Drug: drospirenone 4 mg oral tablet or drospirenone 3.5 mg chewable tablet · For: Change in Bone Mineral Density; Bone Loss
Sites: Phoenix, Arizona; Aurora, Colorado; Boynton Beach, Florida · 37 sites in all
- Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria ComponentPivotal-lookingCompleted
Institute of Tropical Medicine, BelgiumAcademic, hospital or other
NCT00680732 · 1,370 participants · Start Jun 2003 · Primary completion Oct 2006
Drug: Chloroquine (CQ); Sulphadoxyne-pyrimethamine (SP) · For: Malaria; Malaria in Pregnancy
Sites: Bobo-Dioulasso, Burkina Faso
- Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGardPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT03124160 · 1,105 participants · Start May 26, 2017 · Primary completion Jun 6, 2022
Drug: Mona Lisa® NT Cu380 Mini; ParaGard® TCu380A · For: Healthy Women; Female Contraception
Sites: Los Angeles, California; Sacramento, California; San Francisco, California · 16 sites in all
- Long-Acting Reversible ContraceptionPivotal-lookingCompleted
FHI 360Academic, hospital or other
NCT01299116 · 916 participants · Start Dec 2011 · Primary completion Jun 2016
Drug: DMPA; oral contraceptives and 3 more · For: Contraception
Sites: Chapel Hill, North Carolina
- Postplacental Copper Intrauterine Device Versus Postpartum Progesterone-only Pills on Uterine Niche FormationPivotal-lookingCompleted
Benha UniversityAcademic, hospital or other
NCT07264933 · 750 participants · Start Feb 12, 2025 · Primary completion Aug 5, 2025
Drug: progesterone-only pills · For: Scar Niche; Myometrial Remodeling; Contraceptive Device; Complications and 1 more
Sites: Banhā, Egypt
- RAPID EC - Rct Assessing Pregnancy With Intrauterine Devices for ECPivotal-lookingCompleted
University of UtahAcademic, hospital or other
NCT02175030 · 711 participants · Start Aug 2016 · Primary completion Feb 2020
Drug: Copper IUD; Levonorgestrel IUD · For: Contraception
Sites: Logan, Utah; Ogden, Utah; Orem, Utah · 6 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- device breakage11,399
- device expulsion11,259
- complication of device removal10,261
- foreign body in reproductive tract8,905
- complication of device insertion8,360
- device dislocation7,298
- pain6,048
- embedded device4,782
- reproductive complication associated with device3,566
- emotional distress3,129
- anxiety3,117
- off label use2,864
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 11 |
| 2008 | 110 |
| 2009 | 58 |
| 2010 | 139 |
| 2011 | 187 |
| 2012 | 65 |
| 2013 | 40 |
| 2014 | 243 |
| 2015 | 3,156 |
| 2016 | 3,078 |
| 2017 | 3,430 |
| 2018 | 1,080 |
| 2019 | 7,055 |
| 2020 | 3,507 |
| 2021 | 3,298 |
| 2022 | 2,204 |
| 2023 | 4,300 |
| 2024 | 3,086 |
| 2025 | 3,247 |
| 2026 | 4,850 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Environmental toxic metal contaminants and risk of cardiovascular disease: systematic review and meta-analysis.
Chowdhury R, Ramond A, O'Keeffe LM, et al. · BMJ 2018 · Meta-Analysis, Systematic Review
- A systematic review on clinical effectiveness, side-effect profile and meta-analysis on continuation rate of etonogestrel contraceptive implant.
Moray KV, Chaurasia H, Sachin O, et al. · Reprod Health 2021 · Meta-Analysis, Systematic Review
- Micronutrient deficiencies in patients with celiac disease: A systematic review and meta-analysis.
Lamjadli S, Oujamaa I, Souli I, et al. · Int J Immunopathol Pharmacol 2025 · Systematic Review, Meta-Analysis
- Genital inflammatory status and the innate immune response to contraceptive initiation.
Radzey N, Harryparsad R, Meyer B, et al. · Am J Reprod Immunol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Copper in colorectal cancer patients: a systematic review and meta-analysis.
Muñoz-Bravo C, Marín-Burdallo I, González-Herrera L, et al. · Carcinogenesis 2025 · Systematic Review, Meta-Analysis
- Effects of tetrathiomolybdate on copper metabolism in healthy volunteers and in patients with Wilson disease.
Kirk FT, Munk DE, Swenson ES, et al. · J Hepatol 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Coopersurgical
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.